(Alliance News) - GlaxoSmithKline PLC on Friday said it started shipping its quadrivalent influenza vaccines to US healthcare providers and pharmacies for the 2021-22 flu season.
The move follows a licensing and lot-release approval from the US Food & Drug Administration's Center for Biologics Evaluation & Research.
The FTSE 100-listed drugmaker said it expects to distribute to the US more doses than it has in any previous influenza season, with a record supply of more than 50 million doses.
"The flu remains a serious and unpredictable disease that can result in mild to severe illness. As more people are vaccinated against Covid-19 and we return to more normal, social activities, it is important that anyone over the age of six months is vaccinated against the flu," said Leonard Friedland, director of Scientific Affairs & Public Health at GSK Vaccines.
GSK shares closed 0.6% higher in London on Friday at 1,417.40 pence each.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)
